Tikcro Technologies (TIKRF) 0.5300 $TIKRF Tikcro

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tikcro Technologies (TIKRF) 0.5300 $TIKRF

Tikcro Technologies Reports Fourth Quarter and Year End 2014 Results
PR Newswire - Tue Mar 10, 7:30AM CDT
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the fourth quarter and the year ended December 31, 2014.

Tikcro Technologies Announces Shareholders' Meeting
PR Newswire - Wed Feb 18, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that an Extraordinary General Meeting of Shareholders will be held on March 25, 2015 at 12:00 p.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.

Tikcro Signs Research and License Agreement Regarding Cancer Immune Checkpoint Antibodies
PR Newswire - Tue Dec 30, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel. This agreement is for the development of new antibodies originating from specified research at the Weizmann Institute of Science addressing identified targets of cancer immune checkpoints.

Tikcro Technologies Announces 2014 Annual General Meeting
PR Newswire - Mon Nov 24, 8:20AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that its Annual General Meeting of Shareholders will be held on December 29, 2014 at 12:00 p.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.

Tikcro Technologies Reports Third Quarter 2014 Results
PR Newswire - Thu Nov 13, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the third quarter ended September 30, 2014.

Tikcro Technologies Reports Second Quarter 2014 Results
PR Newswire - Wed Jul 30, 8:30AM CDT
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the second quarter ended June 30, 2014.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles